Orgenesis
Business Services · Maryland, United States · 51-200 Employees
View Company Info for Free
Overview
Headquarters
20271 Goldenrod Ln, Germantown, Maryland...Phone Number
(480) 659-6404Website
www.orgenesis.comRevenue
<$5 MillionStock Symbol
ORGSIndustry
ZI Rank: 1
Signal Type
Dec
Jan
Feb
Mar
Apr
May
ZI Rank
2
1
1
2
1
1
About Orgenesis
Orgenesis is a global biotech company working to unlock the full potential of cell and gene therapies (CGTs) in an affordable and accessible format at the point of care. The Orgenesis POCare Platform is comprised of three enabling components: a pipeline of licensed POCare Therapeutics that are processed and produced in closed, automated POCare Technology systems across a collaborative POCare Network. Orgenesis identifies promising new therapies and leverages its POCare Platform to provide a rapid, globally harmonized pathway for these therapies to reach and treat large numbers of patients at lowered costs through efficient, scalable, and decentralized production. The POCare Network brings together patients, doctors, industry partners, research institutes and hospitals worldwide to achieve harmonized, regulated clinical development and production of the therapies. www.orgenesis.com.Explore more
Orgenesis Org Chart
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is Orgenesis your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Check out if Orgenesis is spiking on competitors!
Website visits: Recent activity has been detected on your website
Earning: See what the market has to say on Orgenesis recently announced quarterly report
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Funding: Get notified immidiatlly once Orgenesis has new funding data
Click to see if Orgenesis had a recent Job posting/layoffs
Product Launch: Get notified when Orgenesis launches new products
Check if Orgenesis has recently received funding, and reach out quickly before it becomes old news!
Orgenesis, which may be a good buyer, showed buying intent in Masked Content Topic
Congratulate Masked Content for being promoted to Masked Content at Orgenesis
Recommended Actions
Introduce yourself to Masked Content, who has shown a strong intent to purchase lately
Find 3 more new buyers
Compare Similar Companies to Orgenesis
Compare insights from companies similar to Orgenesis, focusing on performance, financial data, growth rates, and unique benchmarks to identify key industry trends and opportunities.
Revenue
Number of Employees
Type
Funding
Founded In
Company Profile Activity
Activity Insights
Orgenesis is experiencing very low activity levels compared to other companies in the Business Services sector.
What does this means?
Orgenesis is drawing exceptional interest within the Business Services industry, suggesting notable developments or strong market momentum, learn more about Orgenesis.
Orgenesis financials insights
Gather financial insights about Orgenesis, including details on funding rounds, investors, total funding, and acquisitions, to gain a comprehensive understanding of their financial strategy.
2022
Unspecified
$50M
2023
Private Equity
$5M
Orgenesis Tech Stack
A closer look at the technologies used by Orgenesis
Most Recent Scoops
New Hire
Executive Move
Executive Moves, New Hire
Left Company
Executive Move
Executive Moves, Left Company
Left Company
Executive Move
Executive Moves, Left Company
Earnings
Earnings
Executive Moves, Lateral Move, Engineering, Personnel Moves, Software, Industrial Engineering, Industry Software
Orgenesis News & Media
Orgenesis Provides Third Quarter 2024 Business Update
GERMANTOWN, Md., Nov. 13, 2024 (GLOBE NEWSWIRE) -- Orgenesis Inc. (OTCQX: ORGS) (“Orgenesis” or the “Company”), a global biotech company working to unlock the full potential of cell and gene therapies (CGT) in order to improve access and outcomes in healthcare, today provided a business update for the third quarter ended September 30, 2024.Orgenesis Commences Trading on OTCQX® Best Market
Reports Plans to Reapply for Nasdaq ListingOrgenesis Announces Reverse Stock Split
GERMANTOWN, Md., Sept. 23, 2024 (GLOBE NEWSWIRE) -- Orgenesis Inc. (Nasdaq:ORGS) (“Orgenesis” or the “Company”) today announced that its Board of Directors has approved a 1-for-10 reverse stock split of the Company’s common stock, par value $0.0001, which will be effective at 5:00 pm Eastern Time on September 24, 2024. The Company’s common stock will continue to be traded on The Nasdaq Capital Market on a split-adjusted basis beginning on September 25, 2024, under the Company’sBalfour Capital Group Joins Forces with Harley Street Healthcare Group and Orgenesis to Revolutionize Healthcare
OTTAWA, CANADA, August 29, 2024 /EINPresswire.com/ -- Balfour Capital Group (BCG) is thrilled to announce a groundbreaking strategic partnership with the joint venture initiative of Harley Street Healthcare Group (HSHG) and Orgenesis Inc., which aims to …
Read more news
Top Business Services Companies
Top companies in Canada by revenue
Top companies in Australia by revenue
Top companies in New Zealand by revenue
Frequently Asked Questions Regarding Orgenesis
Sign Up For FreeTo access detailed company insights
Orgenesis is a global biotech company working to unlock the full potential of cell and gene therapies (CGTs) in an affordable and accessible format at the point of care. The Orgenesis POCare Platform is comprised of three enabling components: a pipeline of licensed POCare Therapeutics that are processed and produced in closed, automated POCare Tech... Read More
